Evidence map›Paper›PMID 26136832›Full record

ArticleMolecular cytogenetics2015

High rates of submicroscopic aberrations in karyotypically normal acute lymphoblastic leukemia.

Moneeb A K Othman, Joana B Melo, Isabel M Carreira, Martina Rincic, Anita Glaser, Beata Grygalewicz, Bernd Gruhn, Kathleen Wilhelm, Katharina Rittscher, Britta Meyer and 3 more

Open access · goldAbstract read
In one paragraph

Article in Molecular cytogenetics, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
3.3field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 26 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Complex karyotype with crypticOncology letters · 2020
    Article
  5. Article
  6. Review
  7. NovelExperimental hematology & oncology · 2019
    Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 6 institutions in 4 countries.

Moneeb A K OthmanJena University Hospital, Friedrich Schiller University, Institute of Human Genetics, Jena, Germany.
Joana B MeloLaboratory of Cytogenetics and Genomics, Faculty of Medicine, University of Coimbra, Coimbra, Portugal ; CIMAGO, Centro de Investigação em Meio Ambiente, Genéticae Oncobiologia, Coimbra, Portugal.
Isabel M CarreiraLaboratory of Cytogenetics and Genomics, Faculty of Medicine, University of Coimbra, Coimbra, Portugal ; CIMAGO, Centro de Investigação em Meio Ambiente, Genéticae Oncobiologia, Coimbra, Portugal.
Martina RincicJena University Hospital, Friedrich Schiller University, Institute of Human Genetics, Jena, Germany ; Croatian Institute of Brain Research, Zagreb, Croatia.
Anita GlaserJena University Hospital, Friedrich Schiller University, Institute of Human Genetics, Jena, Germany.
Beata GrygalewiczCytogenetic Laboratory, Maria Sklodowska-Curie Memorial Cancer Centre and Institute, Warsaw, Poland.
Bernd GruhnDepartment of Pediatrics (Oncology and Hematology), Jena University Hospital, Friedrich Schiller University, Jena, Germany.
Kathleen WilhelmJena University Hospital, Friedrich Schiller University, Institute of Human Genetics, Jena, Germany ; Department of Pediatrics (Oncology and Hematology), Jena University Hospital, Friedrich Schiller University, Jena, Germany.
Katharina RittscherJena University Hospital, Friedrich Schiller University, Institute of Human Genetics, Jena, Germany.
Britta MeyerZytoVision GmbH, Bremerhaven, Germany.
Maria Luiza Macedo SilvaCytogenetics Department, Bone Marrow Transplantation Unit, National Cancer Institute, Rio de Janeiro, RJ Brazil ; Post Graduation Program in Oncology, National Cancer Institute (INCA), Rio de Janeiro, RJ Brazil.
Terezinha de Jesus Marques SallesPediatric Oncohematology Center, Hospital Oswaldo Cruz/ Pos Graduation Course of the Faculty of Medical Sciences, University of Pernambuco, Recife, PE Brazil.
Thomas LiehrJena University Hospital, Friedrich Schiller University, Institute of Human Genetics, Jena, Germany.
Friedrich Schiller University Jena · DEInstituto Português de Oncologia de Coimbra Francisco Gentil · PTJena University Hospital · DEInstituto Nacional do Câncer · BRThe Maria Sklodowska-Curie National Research Institute of Oncology · PLUniversidade de Pernambuco · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAcute lymphoblastic leukemia (ALL) is not a single uniform disease. It consists of several subgroups with different cytogenetic and molecular genetic aberrations, clinical presentations and outcomes. Banding cytogenetics plays a pivotal role in the detection of recurrent chromosomal rearrangements and is the starting point of genetic analysis in ALL, still. Nowadays, molecular (cyto)genetic tools provide substantially to identify previously non-detectable, so-called cryptic chromosomal aberrations in ALL. However, ALL according to banding cytogenetics with normal karyotype - in short cytogenetically normal ALL (CN-ALL) - represent up to ~50 % of all new diagnosed ALL cases. The overall goal of this study was to identify and characterize the rate of cryptic alterations in CN-ALL and to rule out if one single routine approach may be sufficient to detect most of the cryptic alterations present.

resultsSixty-one ALL patients with CN-ALL were introduced in this study. All of them underwent high resolution fluorescence in situ hybridization (FISH) analysis. Also DNA could be extracted from 34 ALL samples. These DNA-samples were studied using a commercially available MLPA (multiplex ligation-dependent probe amplification) probe set directed against 37 loci in hematological malignancies and/or array-comparative genomic hybridization (aCGH). Chromosomal aberrations were detected in 21 of 61 samples (~34 %) applying FISH approaches: structural abnormalities were present in 15 cases and even numerical ones were identified in 6 cases. Applying molecular approaches copy number alterations (CNAs) were detected in 27/34 samples. Overall, 126 CNAs were identified and only 34 of them were detectable by MLPA (~27 %). Loss of CNs was identified in ~80 % while gain of CNs was present in ~20 % of the 126 CNAs. A maximum of 13 aberrations was detected per case; however, only one aberration per case was found in 8 of all in detail studied 34 cases. Of special interest among the detected CNAs are the following new findings: del(15)(q26.1q26.1) including CHD2 gene was found in 20 % of the studied ALL cases, dup(18)(q21.2q21.2) with the DCC gene was present in 9 % of the cases, and the CDK6 gene in 7q21.2 was deleted in 12 % of the here in detail studied ALL cases.

conclusionsIn conclusion, high resolution molecular cytogenetic tools and molecular approaches like MLPA and aCGH need to be combined in a cost-efficient way, to identify disease and progression causing alterations in ALL, as majority of them are cryptic in banding cytogenetic analyses.

Indexed as

Acute lymphoblastic leukemia (ALL)Array-comparative genomic hybridization (aCGH)Cryptic rearrangementsFluorescence in situ hybridization (FISH)Multiplex ligation-dependent probe amplification (MLPA)Multitude multicolor banding (mMCB)

Identifiers

PMID26136832
PMCPMC4486437
OpenAlexW1821861427

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.